feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

CAT 2025 result expected soon

trending

Single higher education regulator

trending

South Africa Women win series

trending

Lumbini Lions win NPL

trending

PUBG Mobile Esports 2026 Roadmap

trending

Akshay praises Akshaye Khanna's acting

trending

Delhi NCR GRAP-IV imposed

trending

Kapil Sharma on Laughter Chefs

trending

December meteor shower in India

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / MHT Myths Busted: What You Need to Know for Brain Aging

MHT Myths Busted: What You Need to Know for Brain Aging

12 Dec

•

Summary

  • Starting MHT around menopause may support brain health.
  • Later MHT starts may increase dementia risk and tau buildup.
  • Different MHT types and delivery methods impact brain health.
MHT Myths Busted: What You Need to Know for Brain Aging

Early findings from the Women's Health Initiative in the early 2000s raised concerns about menopause hormone therapy (MHT), suggesting increased risks for heart disease, stroke, and cancer. However, subsequent re-analysis of this data has refined understanding, indicating that for many women, MHT can be safely prescribed around menopause to manage symptoms, with benefits often outweighing risks.

The critical window hypothesis highlights that initiating MHT during the menopausal transition may support brain health, whereas starting it years later could be linked to cognitive decline. Recent studies suggest varied outcomes, with some women experiencing cognitive benefits, while others see no negative impact. However, later MHT initiation has been associated with increased tau protein buildup, a marker for Alzheimer's disease.

Furthermore, the type and delivery method of MHT significantly influence its effects. Newer forms like 17-beta estradiol are often preferred over older combinations, and transdermal methods (patches, gels) may carry fewer risks than oral pills by bypassing the liver. MHT is not a dementia prevention strategy but can support well-being and potentially brain health for those who struggle with menopause symptoms.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The WHI initially reported that women on MHT had higher risks of heart disease, stroke, breast cancer, and dementia.
Yes, studies suggest that starting MHT at age 65 or older, or more than five years after menopause, may increase the risk of dementia.
No, different types of MHT and delivery methods have varying effects on brain health; some may support cognition while others do not.

Read more news on

Healthside-arrow

You may also like

US Shutdown's Ripple Effect Hits Companies

11 Dec • 11 reads

article image

FDA Lifts Hormone Therapy Warnings: A New Era for Menopause Relief

5 Dec • 24 reads

article image

Women's Health Crisis: Decades of Neglect Exposed

4 Dec • 56 reads

Berry's Outrage Prompts Newsom U-Turn on Menopause Bill

5 Dec • 19 reads

article image

WHO Backs New Obesity Drugs: A Turning Point?

1 Dec • 144 reads

article image